Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to repurpose drug to battle rare MPS diseases
The Icahn School of Medicine at Mount Sinai has entered into two exclusive licenses to develop the drug pentosan polysulfate sodium for the treatment of mucopolysaccharidosis (MPS), with Australia-based company Paradigm Biopharmaceuticals Ltd. (ASX: PAR) and ReqMed Company, Ltd. of Japan. MPS is a group of 11 lysosomal storage diseases, metabolic disorders caused by genetic…